Mosaic Biosciences announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery.
Malavi Madireddi and Scott Glaser Bring Additional Deep Knowledge and Experience to Senior Leadership Team
BOULDER, Colo.--(BUSINESS WIRE)-- Mosaic Biosciences, a drug discovery organization that provides comprehensive protein and antibody therapeutics research expertise to its biotech, biopharma, and academic partners, today announced two strategic leadership additions to its team: Malavi Madireddi, PhD, as Senior Vice President, Drug Discovery, and Scott Glaser, PhD, as Senior Vice President, Biologics Discovery. Both recognized leaders join the company as it grows to meet increased demand for its comprehensive and integrated drug discovery research services.
“Our commitment to providing our partners with the best collaborative therapeutic discovery engine is underlined by the addition of these two world-class biotechnology leaders to our team,” said Eric Furfine, co-CEO & CSO. “Malavi’s impressive knowledge of biological complexity and its application to clinical indications, joined to Scott’s strategic expertise in protein therapeutic drug discovery, development, and clinical viability, significantly increases the already high value we offer current and prospective partners.”
Prior to joining Mosaic Biosciences, Malavi provided consulting to early-stage VC-founded stealth companies, based on her more than 25 years of successfully leading small molecule and biologic drug discovery teams across multiple therapeutic areas and target classes. In her most recent company position as the Head of Innovative Collaborations, Medical Affairs, Bristol Myers Squibb (BMS), Malavi applied her drug discovery insights to drive strategic external scientific collaborations and support Medical Evidence Generation. This position followed many years of direct scientific research and leadership in multiple disease areas across BMS, including autoimmune and metabolic diseases (e.g., obesity, diabetes, and NASH). She also served as the Head of Clinical Development for JDRF-International in New York.
“I am excited to leverage my drug discovery and clinical development expertise to further position Mosaic Biosciences as the partner of choice for discovering innovative protein therapeutics in a disease agnostic manner,” said Malavi. “The current impact of the Inflation Reduction Act together with cutbacks on R&D resources in Biopharma Companies puts Mosaic Biosciences in a unique position to redefine efficient, collaborative drug hunting, without compromising on the quality of therapies that are brought forward, thereby creating exceptional value for our clients.”
Scott also joins Mosaic Biosciences following several years of active consultant work based on his more than 25 years of successful biopharma experience in streamlining and optimizing the discovery and development of new protein therapeutics. Over his career Scott has contributed to over 50 discovery programs, with multiple molecules advancing into clinical development. He has also pioneered protein technologies, demonstrated by his co-inventorship of 23 issued US patents and multiple pending applications. His most recent corporate position was Director of Antibody Therapeutics for The Genomics Institute of the Novartis Research Foundation (GNF) where he led antibody discovery and platform development efforts. Scott also served at Pfizer as Sr. Director and Site Head of the San Diego Centers for Therapeutic Innovations (CTI), where he was instrumental in building the biologic discovery research team and participated in implementing CTI’s model for academic-industry collaboration. Prior to his Pfizer tenure, Scott led the Antibody Therapeutics team at Biogen Idec.
“Mosaic Biosciences has a strong history of technical innovations and partner support that makes it a leader in the discovery of successful next-generation protein therapeutics,” said Scott. “I look forward to working closely with our talented and dedicated team, and our world class clients.”
About Mosaic Biosciences, Inc.
Mosaic Biosciences is pioneering a new model of protein-based drug discovery research to provide current and emerging biotech, biopharma, and academic customers with a comprehensive therapeutic discovery, characterization, and optimization platform. Mosaic Biosciences’ partners get full access to our cutting-edge and proprietary tools, data-driven approaches, and an experienced and nimble multidisciplinary team of smart and collaborative scientists, all of whom are driven by their shared commitment to finding new drugs to improve human health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402024721/en/
Contacts
Media:
Christine Quern
617-650-8497
christine@theyatesnetwork.com
Mosaic Biosciences:
Fintan Steele
617-816-9834
fintan@mosaicbio.com
Source: Mosaic Biosciences, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240402024721/en
